These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29562531)

  • 1. The Rationale Behind the New Alzheimer's Disease Conceptualization: Lessons Learned During the Last Decades.
    Molinuevo JL; Minguillon C; Rami L; Gispert JD
    J Alzheimers Dis; 2018; 62(3):1067-1077. PubMed ID: 29562531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.
    Ruan Q; D'Onofrio G; Sancarlo D; Bao Z; Greco A; Yu Z
    BMC Geriatr; 2016 May; 16():104. PubMed ID: 27184250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis.
    Parnetti L; Chipi E; Salvadori N; D'Andrea K; Eusebi P
    Alzheimers Res Ther; 2019 Jan; 11(1):7. PubMed ID: 30646955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evolution of the diagnostic frontiers of Alzheimer's disease and new therapeutic possibilities].
    Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):38-44. PubMed ID: 36412155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
    Cavedo E; Lista S; Khachaturian Z; Aisen P; Amouyel P; Herholz K; Jack CR; Sperling R; Cummings J; Blennow K; O'Bryant S; Frisoni GB; Khachaturian A; Kivipelto M; Klunk W; Broich K; Andrieu S; de Schotten MT; Mangin JF; Lammertsma AA; Johnson K; Teipel S; Drzezga A; Bokde A; Colliot O; Bakardjian H; Zetterberg H; Dubois B; Vellas B; Schneider LS; Hampel H
    J Prev Alzheimers Dis; 2014 Dec; 1(3):181-202. PubMed ID: 26478889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
    Dong A; Toledo JB; Honnorat N; Doshi J; Varol E; Sotiras A; Wolk D; Trojanowski JQ; Davatzikos C;
    Brain; 2017 Mar; 140(3):735-747. PubMed ID: 28003242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer's Disease.
    García-Escobar G; Puig-Pijoan A; Puente-Periz V; Fernández-Lebrero A; María Manero R; Navalpotro-Gómez I; Suárez-Calvet M; Grau-Rivera O; Contador-Muñana J; Cascales-Lahoz D; Duran-Jordà X; Boltes N; Pont-Sunyer MC; Ortiz-Gil J; Carrillo-Molina S; López-Villegas MD; Abellán-Vidal MT; Martínez-Casamitjana MI; Hernández-Sánchez JJ; Padrós-Fluvià A; Peña-Casanova J; Sánchez-Benavides G
    J Alzheimers Dis; 2023; 92(4):1303-1321. PubMed ID: 37038810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multipredictor risk models for predicting individual risk of Alzheimer's disease.
    Hou XH; Suckling J; Shen XN; Liu Y; Zuo CT; Huang YY; Li HQ; Wang HF; Tan CC; Cui M; Dong Q; Tan L; Yu JT;
    J Transl Med; 2023 Oct; 21(1):768. PubMed ID: 37904154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.
    Assunção SS; Sperling RA; Ritchie C; Kerwin DR; Aisen PS; Lansdall C; Atri A; Cummings J
    Alzheimers Res Ther; 2022 Apr; 14(1):54. PubMed ID: 35440022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for preclinical Alzheimer's disease.
    Tan CC; Yu JT; Tan L
    J Alzheimers Dis; 2014; 42(4):1051-69. PubMed ID: 25024325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Souvenaid for Alzheimer's disease.
    Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When Does Alzheimer's Disease Really Start? The Role of Biomarkers.
    Lloret A; Esteve D; Lloret MA; Cervera-Ferri A; Lopez B; Nepomuceno M; Monllor P
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
    Zhang H; Lyu D; Jia J;
    J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.